The U.S. Food and Drug Administration Friday approved a new HIV drug made by a unit of Johnson & Johnson. (JNJ).
The drug, Edurant, also known by its generic name rilpivirine, was approved for use in combination with other drugs in treating HIV patients who haven't been previously treated with other HIV drugs.
Edurant is made by Tibotec Therapeutics, which is part of Johnson & Johnson.
Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor and works to block HIV viral replication.
"Patients may respond differently to various HIV drugs or experience varied side effects," said Edward Cox, the director of FDA's Office of Antimicrobial Products. "FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy."
Complete article at WSJ : http://on.wsj.com/l3Q7Oi